We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

50 hedge funds and large institutions have $337M invested in Inozyme Pharma in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 13

2.56% more ownership

Funds ownership: 81.69% → 84.25% (+2.6%)

9% less funds holding

Funds holding: 55 → 50 (-5)

11% less capital invested

Capital invested by funds: $379M → $337M (-$42.3M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
50
Holders Change
-5
Holders Change %
-9.09%
% of All Funds
0.87%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
4
Increased
20
Reduced
13
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$4.56M
2
DM
Deerfield Management
New York
+$3.74M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.46M
4
O
OrbiMed
New York
+$3.28M
5
BCM
Burrage Capital Management
Massachusetts
+$1.27M

Top Sellers

Rank Fund Capital Flow
1
CCM
CAAS Capital Management
New York
-$3.52M
2
NHAS
Novo Holdings A/S
Denmark
-$1.77M
3
Millennium Management
Millennium Management
New York
-$1.53M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.21M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$338K
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
51
CAAS Capital Management
New York
– -$3.52M -177,502 Closed
Susquehanna International Group
52
Susquehanna International Group
Pennsylvania
– -$338K -17,091 Closed
California Public Employees Retirement System
53
California Public Employees Retirement System
California
– -$285K -14,400 Closed
State of Wisconsin Investment Board
54
State of Wisconsin Investment Board
Wisconsin
– -$226K -11,400 Closed
LCM
55
Laurion Capital Management
New York
– -$203K -10,250 Closed
PNC Financial Services Group
56
PNC Financial Services Group
Pennsylvania
– -$180K -9,136 Closed
CLOS
57
Compagnie Lombard Odier SCmA
Switzerland
– -$50K -2,525 Closed
SO
58
STRS Ohio
Ohio
– -$39K -2,000 Closed
Bank of Montreal
59
Bank of Montreal
Ontario, Canada
– -$7K -388 Closed
1 2
3

INZY Hedge Fund Activity: Q2 2021 in Review

50 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2021, worth a combined $337M — down 11% from $379M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of INZY and 4 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 20 added.

The largest buyer was Wellington Management Group, adding an estimated $4.56M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $3.52M sold.

  • 50 institutional investors held Inozyme Pharma (INZY) as of Q2 2021, down from 55 in Q1 2021.
  • Funds reported $337M of Inozyme Pharma stock for Q2 2021, down 11% quarter-over-quarter.
  • 4 funds opened new Inozyme Pharma positions in Q2 2021 and 9 closed out, a net change of -5 holders.
  • The largest Inozyme Pharma buyer in Q2 2021 was Wellington Management Group, an estimated $4.56M added.
  • The largest Inozyme Pharma seller in Q2 2021 was CAAS Capital Management, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2021.